While comparing the CEA levels of breast cancer-bearing animals (Group-II) with the animals of withaferin-A treated animals (Group-III) are having less levels of CEA(p<0.001), which indicates that the Withaferin-A shows its antitumor activity due to whichthe animals show prognosis in treatment. Here, CEACAM5 is linked to breast cancer.